Source Genomics is the first UK-based commercial service provider of Olink Proteomics. The company has partnered with Olink to maximise the power of proteomics, providing high-throughput and scalable biomarker discovery for laboratory projects with unparalleled specificity.
Olink uses innovative Proximity Extension Assay (PEA) technology to measure large numbers of proteins, supporting high-quality biomarker discovery. By combining the PEA protein technology with NGS, Olink allows researchers to conduct high-throughput proteomics without compromising specificity and sensitivity of the assay. This breakthrough in genomic analysis technologies requires minimal sample, less than a drop of blood, while maintaining specificity and sensitivity at the highest level.
Olink Explore panels are categorised into four disease areas: cardiometabolic, inflammation, neurology and oncology, elevating the potential for biomarker discovery in a wide range of health and disease landscapes:
- Identification of novel drug targets
- Disease prediction and patient stratisfication
- In-vivo/in-vitro testing in preclinical research
- Aid understanding of real-time human biology.
Olink provides free consultation at initiation and projects are assigned to an experienced scientist as Project Manager to provide support and updates throughout the project and post data delivery.
Learn more at https://sourcebioscience.com/genomics/olink/.
